(b)(4).This spontaneous case, reported by a consumer who contacted the company to report adverse events and product complaints (pc), concerned a (b)(6) (at the time of initial report) female patient of an unspecified origin.Medical history included diabetes since 2014.Concomitant medication included insulin glargine for an unknown indication.The patient received insulin lispro (rdna origin) (humalog, 100 u/ml) through a cartridge via a reusable pen humapen luxura half dose (hd) at an unknown dose and frequency via an unknown route of administration for the treatment of an unknown indication, beginning on an unknown date.On an unknown date, after starting insulin lispro treatment, her blood sugars was over 2000 (units and reference range not provided) and she went to the hospital.The event blood glucose increased was considered as serious due to medical significance reason.Her a1c (glycosylated hemoglobin) was over 10 (units and reference range not provided).On an unknown date, when she came back from school, her blood glucose was 530.Sometime in (b)(6) 2018, her blood glucose dropped to 40 and she was given so much of juice, (b)(6) and candy so that her blood glucose should came up.The event blood glucose decreased was considered as serious due to medical significance reason.Also, her two out of four cartridges were broken in the box.She received the box from pharmacy on (b)(6) 2018 and the box was sealed.Her mother opened the seal and the box had only four cartridges instead of five.The top part of the cartridge where the red septum was and the glass was broken and missing.(pc# for cartridge (b)(4), lot# c745492d; (b)(4), lot# c787549a; (b)(4), lot# unknown; (b)(4), lot# c815601c).Information regarding corrective treatment for remaining events and outcome of all the events was not provided.Insulin lispro treatment was continued.The operator of the humapen luxura hd was unknown and his/ her training status was not provided.The humapen luxura hd general duration of use and the suspect humapen luxura hd device duration of use were not reported.The actions taken with the suspect humapen luxura hd was not provided and its return was expected.The reporting consumer did not provide any opinion of relatedness between events and insulin lispro and humapen luxura hd.Edit 25may2018: updated medwatch and european and canadian (eu/ca) fields for expedited device reporting.No new information added.Edit 01jun2018: (b)(4) for the humapen luxura half-dose device was added for expedited device reporting.Edit 01jun2018: updated medwatch fields for expedited device reporting.No new information added.
|